Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sorin wants 10% share of Europe's DES (drug-eluting stent) market by November

This article was originally published in Clinica

Executive Summary

Italian group Sorin is aiming to capture at least 10% of the European market for drug-eluting stents in the first 12 months of sales of its Janus tacrolimus-eluting device. So said CEO Drago Cerchiari in an interview with Clinica. The product was CE-marked in October 2004, and generated sales of E1m ($1.3m) in the first month.

Topics

UsernamePublicRestriction

Register

MT054296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel